---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007744"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:51:36.283745+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q1 net loss $0.16/share; Phase 1b of GT-02287 enrollment underway

## Summary
- Net loss per share $0.16 (basic/diluted) vs $0.22 prior year; cash $9.1M as of March 31, 2025.
- R&D expenses $2.3M (down $0.2M), G&A expenses $2.1M (up $0.2M) compared to Q1 2024.
- Phase 1b study of GT-02287 for Parkinson's disease initiated; first biomarker analysis expected mid-2025.
- Gene Mack appointed CEO effective Jan 6, 2025; Gianluca Fuggetta assumed SVP Finance and PFO role.
- IND submission to FDA expected by year end 2025; Phase 1b completion expected Q4 2025.

## SEC filing metadata
- accession: 0001558370-25-007744
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837025007744/0001558370-25-007744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837025007744/ganx-20250514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007744
- JSON: https://secwatch.observer/filing/0001558370-25-007744.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.